---
title: "Aardvark Therapeutics Executives Increase Their Holdings"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/269582546.md"
description: "Aardvark Therapeutics' CEO Lee Tien-Li and CFO Sun Nelson have increased their holdings in the company. Lee Tien-Li purchased 7,000 shares for $101,395, raising his direct ownership to 1,551,613 shares and indirect ownership to 1,474,028 shares. Sun Nelson acquired 3,000 shares for $43,200, bringing his direct ownership to 108,484 shares."
datetime: "2025-12-13T01:40:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/269582546.md)
  - [en](https://longbridge.com/en/news/269582546.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/269582546.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/269582546.md) | [繁體中文](https://longbridge.com/zh-HK/news/269582546.md)


# Aardvark Therapeutics Executives Increase Their Holdings

Reporter Name

Relationship

Type

Amount

SEC Filing

Lee Tien-Li

Chief Executive Officer, 10% Owner

Purchase

$101,395

Form 4

Sun Nelson

Chief Financial Officer, 10% Owner

Purchase

$43,200

Form 4

Lee Tien-Li, Chief Executive Officer and 10% Owner of Aardvark Therapeutics, has expanded his stake in the company by purchasing 7,000 shares at a price of $14.485 each, resulting in a total transaction value of $101,395. Following this acquisition, Lee Tien-Li's direct ownership in the company amounts to 1,551,613 shares, with an additional 1,474,028 shares held indirectly through a spouse.

Sun Nelson, Chief Financial Officer and 10% owner of Aardvark Therapeutics, also increased his investment in the company by acquiring 3,000 shares at a price of $14.4 per share, totaling $43,200. This transaction brings Nelson's direct ownership to 108,484 shares.

### 相关股票

- [Aardvark Therapeutics (AARD.US)](https://longbridge.com/zh-CN/quote/AARD.US.md)

## 相关资讯与研究

- [Aardvark Therapeutics reports lower-than-expected 2025 net loss](https://longbridge.com/zh-CN/news/280210738.md)
- [Aardvark Therapeutics 10-K: $0 Revenue; $(2.93) EPS](https://longbridge.com/zh-CN/news/280211794.md)
- [Tvardi Therapeutics Warns Animal Welfare Rules Could Raise Costs and Delay Drug Development](https://longbridge.com/zh-CN/news/281500356.md)
- [Aardvark pauses two obesity drug trials as it reviews side effects](https://longbridge.com/zh-CN/news/280219366.md)
- [Palvella Therapeutics Reports Full Year 2025 Financial Results And Provides Corporate Update](https://longbridge.com/zh-CN/news/281179779.md)